Tocilizumab is a medication used in this study to see if it can help improve eye health in patients with a specific type of eye problem called acute anterior ischemic optic neuropathy, which is related to a condition known as giant cell arteritis. In this trial, tocilizumab is given as an injection under the skin once a week for four weeks. It is being tested to see if it works better when used together with standard steroid treatment.

Intravenous Pulse Steroid is a treatment that involves giving high doses of steroids directly into the bloodstream. This method is used to quickly reduce inflammation and is a common treatment for conditions like giant cell arteritis, which can cause serious eye problems. In this study, the steroid treatment is being used alone and in combination with tocilizumab to see which approach is more effective in improving eye health.

Acute Anterior Ischemic Optic Neuropathy associated with Giant Cell Arteritis – This condition involves sudden vision loss due to reduced blood flow to the optic nerve, often linked with inflammation of the arteries in Giant Cell Arteritis. The optic nerve, responsible for transmitting visual information from the eye to the brain, becomes damaged due to insufficient blood supply. Symptoms typically include sudden, painless vision loss in one eye, which may progress to the other eye if untreated. Giant Cell Arteritis, also known as Horton’s Disease, is characterized by inflammation of the large and medium-sized arteries, often affecting the arteries in the head. This inflammation can lead to symptoms such as headaches, jaw pain, and scalp tenderness. The progression of the disease can result in further complications if the inflammation is not controlled.